To explore the biomarkers of ischemic stroke "Yin and Yang syndrome" differentiation and treatment system based on metabolomics

注册号:

Registration number:

ITMCTR2025000896

最近更新日期:

Date of Last Refreshed on:

2025-05-06

注册时间:

Date of Registration:

2025-05-06

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

基于代谢组学探索缺血性中风“阴阳类证”辨治体系生物学标志物的研究

Public title:

To explore the biomarkers of ischemic stroke "Yin and Yang syndrome" differentiation and treatment system based on metabolomics

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于代谢组学探索缺血性中风“阴阳类证”辨治体系生物学标志物的研究

Scientific title:

To explore the biomarkers of ischemic stroke "Yin and Yang syndrome" differentiation and treatment system based on metabolomics

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

丘宇慧

研究负责人:

乔利军

Applicant:

Yuhui Qiu

Study leader:

Lijun Qiao

申请注册联系人电话:

Applicant telephone:

18719389223

研究负责人电话:

Study leader's telephone:

13724105689

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

doctorqiuqiu@gzucm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

qiaolijunwork@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区大德路111号

研究负责人通讯地址:

广东省广州市越秀区大德路111号

Applicant address:

No. 111 Dade Road Yuexiu District Guangzhou City Guangdong Province

Study leader's address:

No. 111 Dade Road Yuexiu District Guangzhou City Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院

Applicant's institution:

Guangdong Hospital of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BE2024-252-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Hospital of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/4/7 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广东省广州市越秀区大德路111号

Contact Address of the ethic committee:

Guangdong Hospital of Traditional Chinese Medicine

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 20 8188 7233

伦理委员会联系人邮箱:

Contact email of the ethic committee:

llbgs@gzucm.edu.cn

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Hospital of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

Guangdong Hospital of Traditional Chinese Medicine

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

具体地址:

广东省广州市越秀区大德路111号

Institution
hospital:

Guangdong Hospital of Traditional Chinese Medicine

Address:

No. 111 Dade Road Yuexiu District Guangzhou City Guangdong Province

经费或物资来源:

广东省中医院中医药科学技术研究专项课题

Source(s) of funding:

Guangdong Provincial Hospital of Traditional Chinese Medicine science and technology research project

研究疾病:

中风

研究疾病代码:

Target disease:

Stroke

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

病例对照研究

Case-Control study

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

旨在通过代谢组学技术,探寻适用于缺血性中风阴阳类证辨证的物质基础研究的可靠方法,寻找并确定缺血性中风阳类证患者、阴类证患者和正常人的血清差异性代谢物。

Objectives of Study:

The aim is to explore a reliable method of material basic research for differentiation of Yin and Yang syndrome of ischemic stroke through metabolomics technology and to find and determine the serum differential metabolites of patients with positive syndrome patients with negative syndrome and normal controls of ischemic stroke.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1.1急性缺血性中风患者入选标准 ①患者同时符合缺血性脑卒中的西医诊断标准,且均经头颅CT和/或MRI确诊。 1)急性起病; 2)局灶性神经功能缺损(一侧面部或肢体无力或麻木,语言障碍等),少数为全面神经功能缺损; 3)症状或体征持续时间不限(当影像学显示有责任缺血性病灶时),或持续24h以上(当缺乏影像学责任病灶时); 4)排除非血管性病因; 5)脑CT/MRI排除脑出血。 ②发病年龄≥18岁; ③发病时间在72小时以内; ④签署知情同意书同意参与本研究。 1.2 健康对照组入选标准: ①年龄≥18岁; ②签署知情同意书同意参与本研究; ③无冠心病、脑卒中、TIA等心脑血管疾病病史。

Inclusion criteria

1.1 Inclusion criteria for patients with acute ischaemic stroke ① The patients also met the western medical diagnostic criteria for ischaemic stroke and all were diagnosed by cranial CT and/or MRI. 1) Acute onset of disease; 2) Focal neurological deficits (weakness or numbness of one side of the face or limbs speech disorders etc.) and in a few cases comprehensive neurological deficits; 3) Symptoms or signs of unlimited duration (when imaging shows a responsible ischaemic lesion) or lasting more than 24h (when imaging of a responsible lesion is lacking); 4) Exclusion of non-vascular causes; 5) Brain CT/MRI to exclude cerebral haemorrhage. ② Age of onset ≥ 18 years; ③ Onset within 72 hours; ④ Signed an informed consent form agreeing to participate in this study. 1.2 Healthy control group inclusion criteria: ① Age ≥18 years old; ② Signed informed consent to participate in this study; ③ No history of coronary heart disease stroke TIA and other cardiovascular diseases.

排除标准:

2.1 急性缺血性中风患者排除标准: ①由脑肿瘤、脑外伤、脑寄生虫病、脑淀粉样血管病、动脉炎,以及颅内血管畸形等病因引起的继发性缺血性中风患者; ②发病时有严重的心脏病、心功能不全、肝功能障碍、肾功能不全,呼吸衰竭、恶性肿瘤,消化道出血等; ③精神病患者; ④妊娠和哺乳期妇女; ⑤存在药物滥用、酒精滥用情况的患者; ⑥正参加其它临床试验的患者。 2.2 健康对照组排除标准: ①精神病患者; ②妊娠和哺乳期妇女; ③存在药物滥用、酒精滥用情况的患者; ④正参加其它临床试验的患者。

Exclusion criteria:

2.1 Exclusion criteria for patients with acute ischaemic stroke: ① Patients with secondary ischaemic stroke caused by brain tumour traumatic brain injury cerebral parasitosis cerebral amyloid angiopathy arteritis and intracranial vascular malformation; ② severe heart disease cardiac insufficiency liver dysfunction renal insufficiency respiratory failure malignant tumour gastrointestinal bleeding at the onset; ③ Psychiatric patients; ④Pregnant and lactating women; ⑤ Patients with drug and alcohol abuse; Patients who are participating in other clinical trials. 2.2 Healthy control group exclusion criteria: ① Psychiatric patients; ② Pregnant and lactating women; (iii) Patients with drug abuse or alcohol abuse; (iv) Patients who are participating in other clinical trials; Patients who are participating in other clinical trials.

研究实施时间:

Study execute time:

From 2025-05-01

To      2026-11-30

征募观察对象时间:

Recruiting time:

From 2025-05-17

To      2026-03-31

干预措施:

Interventions:

组别:

中风阳类证组

样本量:

30

Group:

Stroke Yang type syndrome group

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

健康对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

组别:

中风阴类证组

样本量:

30

Group:

Stroke Yin type syndrome group

Sample size:

干预措施:

干预措施代码:

Intervention:

N/A

Intervention code:

样本总量 Total sample size : 90

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东省

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

单位级别:

三甲医院

Institution/hospital:

Guangdong Hospital of Traditional Chinese Medicine

Level of the institution:

Tertiary Grade A Hospital

测量指标:

Outcomes:

指标中文名:

各组差异性代谢物相关的代谢通路

指标类型:

主要指标

Outcome:

Metabolic pathways related to differential metabolites in each group

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

缺血性中风阴类证、阳类证的差异性代谢物

指标类型:

主要指标

Outcome:

Differential metabolites of Yin and Yang syndrome of ischemic stroke

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 100
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始数据暂不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Raw data is not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

研究者根据原始观察记录,将数据及时、正确、完整、清晰地记录在CRF,每个入选病例必须及时完成病例报告表。本研究中,不涉及到外部数据的转接。移交后,病例报告表的内容不再做修改。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

According to the original observation records the researcher recorded the data in CRF in a timely correct complete and clear manner. Each enrolled case must complete the case report form in time. In this study the transfer of external data is not involved. The contents of the case report form will not be modified after the transfer.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above